CD4+ T cell-derived IL21 regulates stem cell fate in acute myeloid leukemia by activation of p38-MAPK signaling

Self-renewal programs in leukemia stem cells (LSCs) predict poor prognosis in acute myeloid leukemia (AML) patients. We identified CD4+ T cell-derived interleukin (IL) 21 as an important negative regulator of self-renewal of murine and human LSCs, but not hematopoietic stem cells. IL21/IL21R signaling favored asymmetric cell division and differentiation in LSCs through accumulation of reactive oxygen species (ROS) and activation of p38-MAPK signaling, resulting in reduced LSCs number and significantly prolonged survival in murine AML models. In human AML, serum IL21 at diagnosis was identified as an independent positive prognostic biomarker for outcome and correlated with better survival and higher complete remission rate in patients that underwent high-dose chemotherapy. IL21 inhibited primary AML LSCs function in vitro by activating ROS and p38-MAPK signaling and this effect was enhanced by cytarabine treatment. Consequently, promoting IL21/IL21R signaling on LSCs may be a novel approach to decrease stemness and increase differentiation in AML.

[1]  C. Riether,et al.  Regulation of hematopoietic and leukemia stem cells by regulatory T cells , 2022, Frontiers in immunology.

[2]  Sandra Pinho,et al.  Leukemic Stem Cells: From Leukemic Niche Biology to Treatment Opportunities , 2021, Frontiers in Immunology.

[3]  L. Smit,et al.  Escape From Treatment; the Different Faces of Leukemic Stem Cells and Therapy Resistance in Acute Myeloid Leukemia , 2021, Frontiers in Oncology.

[4]  M. Konopleva,et al.  IDH1/IDH2 Inhibition in Acute Myeloid Leukemia , 2021, Frontiers in Oncology.

[5]  D. Bezerra,et al.  Cell signaling pathways as molecular targets to eliminate AML stem cells. , 2021, Critical reviews in oncology/hematology.

[6]  A. Nebreda,et al.  Diversity and versatility of p38 kinase signalling in health and disease , 2021, Nature Reviews Molecular Cell Biology.

[7]  Danfeng Xue,et al.  Emerging role of NRF2 in ROS-mediated tumor chemoresistance. , 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[8]  A. Letai,et al.  Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. , 2020, The New England journal of medicine.

[9]  R. Bruggmann,et al.  Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents , 2020, Nature Medicine.

[10]  Song-Tao Liu,et al.  Cell division symmetry control and cancer stem cells , 2020, AIMS molecular science.

[11]  Zhichen Sun,et al.  Targeting tumors with IL-21 reshapes the tumor microenvironment by proliferating PD-1intTim-3-CD8+ T cells. , 2020, JCI insight.

[12]  Patrick M. Helbling,et al.  Combined single-cell and spatial transcriptomics reveal the molecular, cellular and spatial bone marrow niche organization , 2019, Nature Cell Biology.

[13]  Andreas Keller,et al.  Undulating changes in human plasma proteome profiles across the lifespan , 2019, Nature Medicine.

[14]  C. Récher,et al.  Targeting Myeloperoxidase Disrupts Mitochondrial Redox Balance and Overcomes Cytarabine Resistance in Human Acute Myeloid Leukemia. , 2019, Cancer research.

[15]  Xiaomei Ma,et al.  Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. , 2019, Blood reviews.

[16]  A. D’Alessandro,et al.  Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells. , 2019, Cancer cell.

[17]  S. Nimer.  Faculty Opinions recommendation of Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. , 2018, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[18]  Ø. Bruserud,et al.  Therapeutic targeting of leukemic stem cells in acute myeloid leukemia – the biological background for possible strategies , 2017, Expert opinion on drug discovery.

[19]  C. Bloomfield,et al.  Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation , 2017, The New England journal of medicine.

[20]  R. Majeti,et al.  Biology and relevance of human acute myeloid leukemia stem cells. , 2017, Blood.

[21]  D. Pollyea,et al.  Therapeutic targeting of acute myeloid leukemia stem cells. , 2017, Blood.

[22]  F. Vallières,et al.  Mechanism involved in interleukin‐21‐induced phagocytosis in human monocytes and macrophages , 2017, Clinical and experimental immunology.

[23]  T. Pabst,et al.  CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia , 2017, The Journal of experimental medicine.

[24]  F. Ramos,et al.  Acute myeloid leukemia in the older adults , 2016, Leukemia research reports.

[25]  W. Leonard,et al.  IL-21 Signaling in Immunity , 2016, F1000Research.

[26]  Steven L Salzberg,et al.  HISAT: a fast spliced aligner with low memory requirements , 2015, Nature Methods.

[27]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[28]  C. Schürch,et al.  Regulation of hematopoietic and leukemic stem cells by the immune system , 2014, Cell Death and Differentiation.

[29]  W. Leonard,et al.  Interleukin-21: a double-edged sword with therapeutic potential , 2014, Nature Reviews Drug Discovery.

[30]  Y. Iwakura,et al.  Positive feedback between NF-κB and TNF-α promotes leukemia-initiating cell capacity. , 2014, The Journal of clinical investigation.

[31]  G. Hardiman,et al.  Lis1 regulates asymmetric division in hematopoietic stem cells and in leukemia , 2014, Nature Genetics.

[32]  E. Remmerswaal,et al.  IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells. , 2013, Blood.

[33]  John M. Ashton,et al.  Targeting Aberrant Glutathione Metabolism to Eradicate Human Acute Myelogenous Leukemia Cells* , 2013, The Journal of Biological Chemistry.

[34]  M. Dyer,et al.  Enhancement of CD154/IL4 proliferation by the T follicular helper (Tfh) cytokine, IL21 and increased numbers of circulating cells resembling Tfh cells in chronic lymphocytic leukaemia , 2013, British journal of haematology.

[35]  M. Caligiuri,et al.  A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia , 2013, Leukemia.

[36]  D. LeBrun,et al.  Abundant expression of interleukin-21 receptor in follicular lymphoma cells is associated with more aggressive disease , 2013, Leukemia & lymphoma.

[37]  Wei Shi,et al.  featureCounts: an efficient general purpose program for assigning sequence reads to genomic features , 2013, Bioinform..

[38]  W. Leonard,et al.  IL-21 Restricts Virus-driven Treg Cell Expansion in Chronic LCMV Infection , 2013, PLoS pathogens.

[39]  John M. Ashton,et al.  BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. , 2013, Cell stem cell.

[40]  Wei Li,et al.  RSeQC: quality control of RNA-seq experiments , 2012, Bioinform..

[41]  Guangchuang Yu,et al.  clusterProfiler: an R package for comparing biological themes among gene clusters. , 2012, Omics : a journal of integrative biology.

[42]  Angelo J. Canty,et al.  Stem cell gene expression programs influence clinical outcome in human leukemia , 2011, Nature Medicine.

[43]  W. Telford,et al.  Key role for IL-21 in experimental autoimmune uveitis , 2011, Proceedings of the National Academy of Sciences of the United States of America.

[44]  R. Hills,et al.  Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. , 2010, Blood.

[45]  Wolfram Goessling,et al.  The Wnt/β-Catenin Pathway Is Required for the Development of Leukemia Stem Cells in AML , 2010, Science.

[46]  I. Lossos,et al.  Novel IL-21 signaling pathway up-regulates c-Myc and induces apoptosis of diffuse large B-cell lymphomas. , 2010, Blood.

[47]  G. Smyth,et al.  ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. , 2009, Journal of immunological methods.

[48]  M. Minden,et al.  Outcomes and quality of care in acute myeloid leukemia over 40 years , 2009, Cancer.

[49]  Jeffrey M. Rosen,et al.  The Increasing Complexity of the Cancer Stem Cell Paradigm , 2009, Science.

[50]  K. Sauer,et al.  IL-21 Is Required to Control Chronic Viral Infection , 2009, Science.

[51]  J. Weber,et al.  IL-21R on T Cells Is Critical for Sustained Functionality and Control of Chronic Viral Infection , 2009, Science.

[52]  Daniel Nowak,et al.  Differentiation therapy of leukemia: 3 decades of development. , 2009, Blood.

[53]  Ulrich Mansmann,et al.  An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. , 2008, Blood.

[54]  R. Bataille,et al.  IL-21 Stimulates Human Myeloma Cell Growth through an Autocrine IGF-1 Loop , 2008, The Journal of Immunology.

[55]  R. Meier,et al.  IL‐21 and IL‐21R are not required for development of Th17 cells and autoimmunity in vivo , 2008, European journal of immunology.

[56]  Thomas D. Schmittgen,et al.  Analyzing real-time PCR data by the comparative CT method , 2008, Nature Protocols.

[57]  K. Karube,et al.  IL-21 is expressed in Hodgkin lymphoma and activates STAT5: evidence that activated STAT5 is required for Hodgkin lymphomagenesis. , 2008, Blood.

[58]  W. Leonard,et al.  Interleukin-21: basic biology and implications for cancer and autoimmunity. , 2008, Annual review of immunology.

[59]  Keisuke Ito,et al.  Function of oxidative stress in the regulation of hematopoietic stem cell-niche interaction. , 2007, Biochemical and biophysical research communications.

[60]  I. Weissman,et al.  Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood. , 2007, Cell stem cell.

[61]  S. Sharkis,et al.  A low level of reactive oxygen species selects for primitive hematopoietic stem cells that may reside in the low-oxygenic niche. , 2007, Blood.

[62]  D. Levy,et al.  The molecular basis of IL-21-mediated proliferation. , 2007, Blood.

[63]  M. Kurrer,et al.  IL-21 receptor signaling is integral to the development of Th2 effector responses in vivo. , 2007, Blood.

[64]  P. Kristjansen,et al.  Interleukin 21 therapy increases the density of tumor infiltrating CD8+ T cells and inhibits the growth of syngeneic tumors , 2007, Cancer Immunology, Immunotherapy.

[65]  Arne Traulsen,et al.  (A)Symmetric Stem Cell Replication and Cancer , 2007, PLoS Comput. Biol..

[66]  T. Wynn,et al.  The IL-21 receptor augments Th2 effector function and alternative macrophage activation. , 2006, The Journal of clinical investigation.

[67]  Younghun Jung,et al.  Regulation of SDF-1 (CXCL12) production by osteoblasts; a possible mechanism for stem cell homing. , 2006, Bone.

[68]  J. Dick,et al.  Cancer stem cells: lessons from leukemia. , 2005, Trends in cell biology.

[69]  L. Lanier,et al.  IL-21 Enhances Tumor Rejection through a NKG2D-Dependent Mechanism1 , 2005, The Journal of Immunology.

[70]  J. Dick.  Acute Myeloid Leukemia Stem Cells , 2005, Annals of the New York Academy of Sciences.

[71]  Tak W. Mak,et al.  Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells , 2004, Nature.

[72]  Qingsheng Li,et al.  IL-21 Enhances and Sustains CD8+ T Cell Responses to Achieve Durable Tumor Immunity: Comparative Evaluation of IL-2, IL-15, and IL-211 , 2004, The Journal of Immunology.

[73]  J. Dick,et al.  Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity , 2004, Nature Immunology.

[74]  R. Verhaak,et al.  Prognostically useful gene-expression profiles in acute myeloid leukemia. , 2004, The New England journal of medicine.

[75]  W. Leonard,et al.  In vivo antitumor activity of interleukin 21 mediated by natural killer cells. , 2003, Cancer research.

[76]  M. Tagawa,et al.  Expression of the interleukin-21 gene in murine colon carcinoma cells generates systemic immunity in the inoculated hosts , 2003, Cancer Gene Therapy.

[77]  Daniel G. Tenen,et al.  Disruption of differentiation in human cancer: AML shows the way , 2003, Nature Reviews Cancer.

[78]  A. Sher,et al.  A Critical Role for IL-21 in Regulating Immunoglobulin Production , 2002, Science.

[79]  J. Dick,et al.  Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell , 1997, Nature Medicine.

[80]  M. Caligiuri,et al.  A cell initiating human acute myeloid leukaemia after transplantation into SCID mice , 1994, Nature.

[81]  雁金 大樹.  p38α activates purine metabolism to initiate hematopoietic stem/progenitor cell cycling in response to stress(要約) , 2016 .

[82]  中田 潤,et al.  In vivo eradication of MLL/ENL leukemia cells by NK cells in the absence of adaptive immunity , 2014 .

[83]  W. Leonard,et al.  The Dectin-2 family of C-type lectin-like receptors: an update , 2013, International immunology.